Episode 70: ESMO 2023 - Small Cell Lung Cancer
ESMO 2023 showcased several promising trials in the small-cell lung cancer space. A cancer that continues to send shivers down the spine of budding oncologists for decades. Today, we look at several different classes of drugs, the first being a novel immunotherapy agent, the second a well-known antibody-drug conjugate and the third a synthetic alkaloid analogue. Lurbinectedin and pembrolizumab, sacitizumab govitecan or toripalimab, while all difficult to say five times fast, may change the future of small cell lung cancer. Which is your drug of choice? Tune in to find out if you chose correctly!
Studies discussed in this episode. Subscription may be required
EXTENTORCH (Toripalimab) - https://esmocongress.esmo.org/esmo/esmo2023/en-GB/presentation/639076
LUPER trial (Lurbinectedin + pembrolizumab)- https://esmocongress.esmo.org/esmo/esmo2023/en-GB/presentation/638285
Tropics-03 trial (sacituzumab govitecan) - https://esmocongress.esmo.org/esmo/esmo2023/en-GB/presentation/638286
